AlgiPharma wins NFR funding for basic research projects on biofilms

/in ,

The Research Council of Norway (Norges Forskningsråd (NFR)) has awarded AlgiPharma grants for two new projects “Biofilm” and “Epipharm II” representing a continuation and expansion of the NFR support for AlgiPharma’s alginate oligomer research efforts. These grants are administered under the NFR program for User directed Innovation Arena.

For further information, please contact:
Philip D. Rye R&D Director, +47 97503033; phil.rye@algipharma.com

June 2008

AlgiPharma’s medicinal alginate product gains Orphan Drug Status for Cystic Fibrosis Treatment

/in

AlgiPharma’s medicinal product “Alginate oligosaccharide (G-block) fragment” has been designated as an orphan medicinal product for the following indication: treatment of Cystic Fibrosis. The European Medicines Agency’s Committee for Orphan Medicinal Products recommended that AlgiPharma’s application be accepted by the Commission of the European Communities. The Commission gave final approval on September 14th.

For more information contact:
Yngvar P. Berg, CEO, +47 90044903; yngvar.berg@algipharma.com
Astrid Hilde Myrset, Clinical Director, +47 93026094; astrid.hilde.myrset@algipharma.com

September 2007

AlgiPharma Established

/in

On the initiative of FMC BioPolymer AS, AlgiPharma was established, financed and began operating as an independent company. AlgiPharma is a biopharmaceutical company that aims to develop medicinal products within the areas of respiratory diseases, wound healing and other infectious diseases.

For further information, please contact:
Arne Dessen, Chairman of Board, +47 95170278; arne.dessen@algipharma.com
Yngvar P. Berg, CEO, +47 90044903; yngvar.berg@algipharma.com

August 2006